Le test MeMed COVID-19 Severity reçoit le marquage CE pour la prévision des complications sévères chez les patients atteints de COVID-19
July 27, 2021 02:00 ET
|
MeMed
Le test MeMed COVID-19 Severity reçoit le marquage CE pour la prévision des complications sévères chez les patients atteints de COVID-19MeMed COVID-19 Severity évalue le système immunitaire en temps...
MeMed Key® Wins Red Dot Award for High Design Quality
April 22, 2021 07:00 ET
|
MeMed
MeMed Key® Wins Red Dot Award for High Design Quality HAIFA, April 22, 2021- frog, a leading global design and strategy consultancy, part of...
MeMed and 360Dx Bring Together International Experts for a Timely Discussion on Predicting COVID-19 Severity Using the Host Immune Response
April 13, 2021 07:00 ET
|
MeMed
MeMed and 360Dx Bring Together International Experts for a Timely Discussion on Predicting COVID-19 Severity Using the Host Immune Response HAIFA, Israel, April 13, 2021 – MeMed, a leader in...
Troy Boutelle Joins MeMed as Vice President of Commercial in North America and General Manager, U.S.
January 12, 2021 07:00 ET
|
MeMed
Troy Boutelle Joins MeMed as Vice President of Commercial in North America and General Manager, U.S. Troy brings 20 years of top-flight sales and commercial experience as MeMed expands into the U.S....
MeMed Appoints Industry Veteran Chris Hibberd to its Board of Directors
December 16, 2020 07:12 ET
|
MeMed
MeMed Appoints Industry Veteran Chris Hibberd to its Board of Directors HAIFA, Israel, December 16, 2020 – MeMed, a leader in host immune response-based solutions, today announced that Chris Hibberd...
MeMed Selected to Present at BARDA Industry Day 2020
October 26, 2020 07:00 ET
|
MeMed
MeMed Selected to Present at BARDA Industry Day 2020 Dr. Eran Eden to Give Lightning Talk on October 27 on MeMed’s Advanced Host-Immune Response Technology HAIFA, Israel, October 26, 2020 – MeMed™,...
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution
September 08, 2020 07:00 ET
|
MeMed
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution ...
DiaSorin 与 MeMed 合作开发和商业化基于新型宿主免疫应答的诊断解决方案
September 08, 2020 02:02 ET
|
MeMed
DiaSorin 与 MeMed 合作开发和商业化基于新型宿主免疫应答的诊断解决方案 ...
DiaSorin e MeMed avviano una partnership strategica per lo sviluppo e la commercializzazione di una soluzione diagnostica basata sulla risposta immunitaria dei pazienti
September 08, 2020 01:30 ET
|
MeMed
DiaSorin e MeMed avviano una partnership strategica per lo sviluppo e la commercializzazione di una soluzione diagnostica basata sulla risposta immunitaria dei pazienti Accordo di licenza per...
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution
September 08, 2020 01:30 ET
|
MeMed
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution ...